MC4R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-11. Numbers and descriptions here follow the published literature rather than marketing material.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
In his 1974 defeat, Mizell polled less than three fifths of the total votes that he had received in 1972. The year's Almanac of American Politics called his loss, "one of the most stunning House upsets in 1974." President Gerald R. Ford Jr., a former House colleague, appointed Mizell as Assistant Secretary of Commerce for the Economic Development Administration, a post he held from March 1975 to May 1976. In 1976, Mizell challenged Neal again. He criticized the Democrat for not owning a home in the district, calling him a "soft on defense" liberal that changed positions regularly on economic issues. Neal called his opposition "an out-of-state candidate, being financed with out-of-state money and being staffed with out-of-state people for the benefit of out-of-state interests." The race attracted much attention; according to The Winston-Salem Journal, "In Washington, home of the national Republican and Democratic parties and a variety of political splinter groups, the Neal-Mizell contest is seen as one of the key congressional races in the country. The groups are proving their interest by sizeable contributions of money and service to the two candidates." Both candidates charged the other with being a Washington insider. The Washington Post considered the race "a toss-up." Mizell ran on economic issues, and former governor of California Ronald Reagan came to Winston-Salem in October to speak at a fundraiser for him. Mizell lost, 83,129 (45.7 percent) to 98,789 (54.3 percent).
signal transduction The process by which a chemical, electrical, or mechanical signal is converted into a cellular response, or the transmission or propagation of such a signal through a cell as a series of molecular events known as a signaling pathway. For example, the extracellular interaction of a hormone, growth factor, or some other chemical agonist with a specific cell surface receptor can trigger a cascade of sequential biochemical reactions which propagate through the cell membrane and into the cytoplasm, provoking the synthesis of second messengers and leading to amplification of the signal or activation of other pathways. Other modes of transduction involve agonists which diffuse across the membrane freely, eliciting intracellular changes without amplification, or rapid shifts in cell polarity which transmit electrical impulses, such as those that cause the axons of neural cells to release neurotransmitters at synapses.
Tolkien learnt to paint and draw as a child and continued to do so all his adult life. From early in his writing career, the development of his stories was accompanied by drawings and paintings, especially of landscapes, and by maps of the lands in which the tales were set. He produced pictures to accompany the stories told to his own children, including those later published in Mr Bliss and Roverandom, and sent them elaborately illustrated letters purporting to come from Father Christmas. Although he regarded himself as an amateur, the publisher used the author's own cover art, his maps, and full-page illustrations for the early editions of The Hobbit. He prepared maps and illustrations for The Lord of the Rings, but the first edition contained only the maps, his calligraphy for the inscription on the One Ring, and his ink drawing of the Doors of Durin. Much of his artwork was collected and published in 1995 as a book: J. R. R. Tolkien: Artist and Illustrator. The book discusses Tolkien's paintings, drawings, and sketches and reproduces approximately 200 examples of his work. Catherine McIlwaine curated a major exhibition of Tolkien's artwork at the Bodleian Library, Tolkien: Maker of Middle-earth, accompanied by a book of the same name that analyses Tolkien's achievement and illustrates the full range of the types of artwork that he created.
Sources: en.wikipedia.org
Coagulation for flocculation. The addition of coagulants destabilizes colloidal suspensions by neutralizing their charges, resulting in the aggregation of smaller particles during the coagulation process. Coagulant aids, also known as polyelectrolytes – to improve coagulation and for more robust floc formation. Polyelectrolytes or also known in the field as polymers, usually consist of either a positive or negative charge. The nature of the polyelectrolyte used is purely based on the source water characteristics of the treatment plant. These will usually be used in conjunction with a primary coagulant such as ferric chloride, ferric sulfate, or alum. Chemical precipitation is a common process used to reduce heavy metals concentrations in wastewater. The dissolved metal ions are transformed to an insoluble phase by a chemical interaction with a precipitant agent such as lime. In industrial applications stronger alkalis may be used to effect complete precipitation. In drinking water treatment, the common-ion effect is often used to help reduce water hardness. Flotation uses bubble attachment to separate solids or dispersed liquids from a liquid phase.
== Applications == In biochemistry, the process of breaking down large molecules by splitting their internal bonds is catabolism. Enzymes which catalyse bond cleavage are known as lyases, unless they operate by hydrolysis or oxidoreduction, in which case they are known as hydrolases and oxidoreductases respectively. In proteomics, cleaving agents are used in proteome analysis, where proteins are cleaved into smaller peptide fragments. Examples of cleaving agents used are cyanogen bromide, pepsin, and trypsin.
At the conclusion of the arc, Wolverine takes a leave of absence from the X-Men. By the mid-1990s, Wolverine was one of Marvel's most popular characters, rivaling Spider-Man. In 1995, all of the X-Men related comic books were temporarily replaced by a storyline in an alternate reality, named Age of Apocalypse; the Wolverine series was renamed Weapon X. Following the return to the original timeline, a follower of Apocalypse captures Wolverine and attempts to bond adamantium to his skeleton a second time, with the goal of making him one of Apocalypse's warriors. Wolverine's healing factor and willpower reject the process, but the ensuing stress leads him to regress into a bestial state. Stick, the former mentor of Daredevil, sends Elektra to re-train Wolverine, and heal his psyche. For a few issues of his title, Wolverine remains in a bestial state in which he is less articulate and shrewd. Hama left the Wolverine series with issue #118 (November 1997), and Logan's adamantium was restored at the end of the decade in issue #145 (December 1999).
Sources: en.wikipedia.org
Anagani Satya Prasad is cabinet Minister ( Revenue, Registration & Stamps ) & MLA of Andhra Pradesh from Repalle Constituency in Guntur district, Andhra Pradesh. He was elected to assembly elections in 2014 & 2019 defeating Mopidevi Venkata Ramana of YSRCP and in 2024 defeating Evuri Ganesh of YSRCP.
2-Hydroxybutyrate, the conjugate base of 2-hydroxybutyric acid, is produced in mammalian tissues (principally hepatic) that catabolize L-threonine or synthesize glutathione. Oxidative stress or detoxification demands can dramatically increase the rate of hepatic glutathione synthesis. Under such metabolic stress conditions, supplies of L-cysteine for glutathione synthesis become limiting, so homocysteine is diverted from the transmethylation pathway forming methionine into the transsulfuration pathway forming cystathionine. 2-Hydroxybutyrate is released as a byproduct when cystathionine is cleaved to cysteine that is incorporated into glutathione. Chronic shifts in the rate of glutathione synthesis may be reflected by urinary excretion of 2-hydroxybutyrate. α-hydroxybutyrate may be useful as an early indicator of insulin resistance in non-diabetic subjects. Moreover, elevated serum α-hydroxybutyrate predicts worsening glucose tolerance.
== 2A function in FMDV virus == Foot-and-mouth disease virus (FMDV) is a virus in the genus Aphthovirus that causes foot-and-mouth disease in cattle. As a member of the family Picornaviridae, FMDV is a positive-sense, single-stranded RNA virus. 2A is located between the capsid proteins and polymerases and proteases required for the capsid assembly in the late stages of the infection. The incomplete ribosomal skipping during the viral RNA translation mediated by the 2A results in "ribosome drop off" in some cases, after which the translation doesn't restart. This leads to a prevalence of the N-terminal proteins and allows for the increased production of the structural proteins relative to the non-structural proteins.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.